Catalog No.
DHD10499
Description
Mirvetuximab soravtansine is an ADC consisting of an FRA-directed antibody and DM4 used for the study of ovarian cancer and other FRα-positive cancers.
Species reactivity
Human
Clonality
Monoclonal
Target
FRA
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Purification
Purified by Ion Exchange Chromatography.
Applications
Research Grade Biosimilar
Form
Liquid
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ELAHERE, huFR107-SPDB-DM4
Clone ID
Mirvetuximab soravtansine
Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker., PMID:40508029
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters., PMID:40501953
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer., PMID:40501444
State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers., PMID:40489723
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
Ovarian Cancer Therapy., PMID:40389314
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer., PMID:40270982
Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer., PMID:40242965
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial., PMID:40179908
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma., PMID:40150910
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics., PMID:40139025
A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer., PMID:40126684
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate., PMID:40121972
Addressing the challenge of platinum-resistant ovarian cancer: the role of mirvetuximab soravtansine., PMID:40109581
Mirvetuximab soravtansine: current and future applications., PMID:40102896
Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report., PMID:40050918
Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer., PMID:40029935
Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer., PMID:40028469
[Mirvetuximab soravtansine as monotherapy in platinum-resistant ovarian cancer expressing alpha folate receptor]., PMID:40016053
Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells., PMID:39996761
Mirvetuximab soravtansine shines post-PARP inhibitor progression: promising insights from the PICCOLO trial., PMID:39988550
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies., PMID:39970828
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective., PMID:39922351
Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines., PMID:39900344
Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine., PMID:39734248
Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis., PMID:39729462
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know., PMID:39641680
Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy., PMID:39640287
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers., PMID:39631181
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial., PMID:39617145
Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?, PMID:39595996
Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers., PMID:39590153
The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis., PMID:39526448
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary., PMID:39461270
Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer., PMID:39378056
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen., PMID:39307840
Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature., PMID:39281842
Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)., PMID:39228525
[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]., PMID:39191683
Accuracy and Completeness of Large Language Models About Antibody-Drug Conjugates and Associated Ocular Adverse Effects., PMID:39110155
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer., PMID:39082675
Mirvetuximab after anaphylaxis to Paclitaxel: A case report., PMID:39076678
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer., PMID:39061184
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities., PMID:38941962
Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases., PMID:38914019
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial., PMID:38858103
Ocular toxicities associated with antibody drug conjugates., PMID:38814581
Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer., PMID:38758856
Corrigendum: Therapeutic strategies targeting folate receptor α for ovarian cancer., PMID:38694498
For research use only. Not for human or drug use.
